Systemic administration of adenosine A(2A) receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: A microdialysis study

Neuroscience

Volumn 100, Issue 1, 2000, Pages 53-62

  Ochi, M ^a   Koga, K ^a   Kurokawa, M ^a   Kase, H ^a   Nakamura, J ^a   Kuwana, Y ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

6 hydroxydopamine; Adenosine A(2A) receptor antagonist; CGS21680; GABA release; microdialysis; striatopallidal neuron

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 AMINOBUTYRIC ACID; ADENOSINE A2A RECEPTOR ANTAGONIST; ISTRADEFYLLINE; OXIDOPAMINE; UNCLASSIFIED DRUG;

4 AMINOBUTYRIC ACID RELEASE; ANIMAL EXPERIMENT; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; CORPUS STRIATUM; GLOBUS PALLIDUS; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT;

ADENOSINE; ANIMALS; CORPUS STRIATUM; EXTRACELLULAR SPACE; GABA ANTAGONISTS; GAMMA-AMINOBUTYRIC ACID; GLOBUS PALLIDUS; MALE; MICROINJECTIONS; OXIDOPAMINE; PHENETHYLAMINES; PURINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PURINERGIC P1; REFERENCE VALUES;

EID: 0034618819     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(00)00250-5     Document Type: Article

References (57)

1. Abbracchio M.P., Flaminio C., Fredholm B.B., Williams M. Purinoceptor nomenclature: a status report. Drug Dev. Res. 28:1993;207-213.
2. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12:1989;366-375.
3. Bennett J.P. Striatal dopamine depletion, dopamine receptor stimulation and GABA metabolism: implications for the therapy of Parkinson's disease. Ann. Neurol. 19:1986;194-197.
4. Boegman R.J., Vincent S.R. Involvement of adenosine and glutamate receptors in the induction of c-fos in the striatum by haloperidol. Synapse. 22:1996;70-77.
5. DeLong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13:1990;281-285.
6. Dixon A.K., Gubitz A.K., Sirinathsinghji D.J.S., Richardson P.J., Freeman T.C. Tissue distribution of adenosine receptor mRNAs in the rat. Br. J. Pharmac. 118:1996;1461-1468.
7. Drew K.L., Ungerstedt U. Pergolide presynaptically inhibits calcium-stimulated release of gamma-aminobutyric acid. J. Neurochem. 57:1991;1927-1930.
8. Ferre S., O'Connor W.T., Fuxe K., Ungerstedt U. The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J. Neurosci. 13:1993;5402-5406.
9. 2 dopamine receptors in rat striatum. Molec. Brain Res. 14:1992;186-195.
10. Griffiths P.D., Sambrook M.A., Perry R., Crossman A.R. Changes in benzodiazepine and acetylcholine receptors in the globus pallidus in Parkinson's disease. J. neurol. Sci. 100:1990;131-136.
11. Hauber W. Involvement of basal ganglia transmitter systems in movement initiation. Prog. Neurobiol. 56:1998;507-540.
12. 3H]CGS21680. Eur. J. Pharmac. 168:1989;243-246.
13. 2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol. 43:1998;507-513.
14. 2A receptor antagonist with anticataleptic activity. Eur. J. Pharmac. 256:1994;263-268.
15. 2A receptors modify motor function in MPTP-treated common marmosets. NeuroReport. 9:1998;2857-2860.
16. 3H]acetylcholine release. J. Neurochem. 62:1994;960-966.
17. Kish S.J., Rajput A., Gilbert J., Rozdilsky B., Chang L.J., Shannak K., Hornykiewicz O. Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss. Ann. Neurol. 20:1986;26-31.
18. Kita H., Kitai S.T. The morphology of globus pallidus projection neurons in the rat: an intracellular staining study. Brain Res. 636:1994;308-319.
19. 2A receptor-mediated modulation of striatal GABA and ACh release. Br. J. Pharmac. 113:1994;43-48.
20. 2a receptor-mediated modulation of striatal acetylcholine release in vivo. J. Neurochem. 66:1996;1882-1888.
21. 2A antagonists in experimental models. Adv. Neurol. 80:1999;121-123.
22. 2 synergism and receptor supersensitivity. Proc. natn. Acad. Sci. USA. 90:1993;7451-7455.
23. Lindefors N., Brodin E., Tossman U., Segovia H., Ungerstedt U. Tissue levels and in vivo release of tachykinins and GABA in striatum and substantia nigra of rat brain after unilateral striatal dopamine denervation. Expl Brain Res. 74:1989;527-534.
24. Lindroth P., Mopper K. High performance liquid choromatography determination of subpicomole amounts of amino acids by precolumn fluorescence derivatization with o-phthaldialdehyde. Analyt. Chem. 51:1979;1667-1674.
25. 2A receptor antagonists in the treatment of movement disorder. CNS Drugs. 10:1998;311-320.
26. Marcotte E.R., Sullivan R.M., Mishra R.K. Striatal G-proteins: effects of unilateral 6-hydroxydopamine lesions. Neurosci. Lett. 169:1994;195-198.
27. 2 receptors: selective location in the human basal ganglia and alterations with disease. Neuroscience. 42:1991;697-706.
28. 2a modulation of electrically-evoked endogenous GABA release from slices of rat globus pallidus. J. Neurochem. 60:1993;2334-2337.
29. 2 receptor interaction in globus pallidus. Synapse. 22:1996;132-138.
30. Mishra R.K., Marshall A.M., Varmuza S.L. Supersensitivity in rat caudate nucleus: effects of 6-hydroxydopamine on the time course of dopamine receptor and cyclic AMP changes. Brain Res. 200:1980;47-57.
31. 2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. J. Neurosci. 15:1996;605-611.
32. Nisbet A.P., Eve D.J., Kingsbury A.E., Daniel S.E., Marsden C.D., Lees A.J., Foster O.J.F. Glutamate decarboxylase-67 messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience. 75:1996;389-406.
33. Nisbet A.P., Foster O.J.F., Kingsbury A., Eve D.J., Daniel S.E., Marsden C.D., Lees A.J. Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience. 66:1995;361-376.
34. Nonaka H., Ichimura M., Takeda M., Nonaka Y., Shimada J., Suzuki F., Yamaguchi K., Kase H. KF17837((E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine), a potent and selective adenosine A2 receptor antagonist. Eur. J. Pharmac. 267:1994;335-341.
35. 1 receptors in rats. NeuroReport. 7:1996;3013-3016.
36. 3H]CGS21680 as a ligand. Naunyn-Schmiedeberg's Arch. Pharmac. 342:1990;85-89.
37. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coodinates. 2nd edn. 1986;Academic, Sydney.
38. 2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur. J. Pharmac. 287:1995;215-217.
39. 2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends pharmac. Sci. 18:1997;338-344.
40. Richardson P.J., Kase H., Jenner P.G. Richardson et al. reply. Trends pharmac. Sci. 19:1998;47-48.
41. 3H)flunitrazepam autoradiography. Brain Res. 531:1990;95-104.
42. Robertson R.G., Graham W.C., Sambrook M.A., Crossman A.R. Further investigations into the pathophysiology of MPTP-induced Parkinsonism in the primate: an intracerebral microdialysis study of gamma-aminobutyric acid in the lateral segment of the globus pallidus. Brain Res. 563:1991;278-280.
43. 2A receptor immunoreactivity in rat striatum. Soc. Neurosci. Abstr. 23:1997;1494.
44. 2A receptors in the rat central nervous system. J. comp. Neurol. 401:1998;163-186.
45. Sagar S.M., Sharp F.R., Curran T. Expression of c-fos protein in brain: metabolic mapping at the cellular level. Science. 240:1988;1328-1331.
46. Samuel D., Kumar U., Nieoullon A. Gamma-aminobutyric acid function in the rat striatum is under the double influence of nigrostriatal dopaminergic and thalamostriatal inputs: two modes of regulation? J. Neurochem. 51:1988;1704-1710.
47. 2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J. Neurochem. 57:1991;1062-1067.
48. 2 receptor mRNA in the human brain. Neurosci. Lett. 130:1991;177-181.
49. 2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J. Neurosci. 13:1993;1080-1087.
50. Segovia J., Tillakaratne N.J.K., Whelan K., Tobin A.J., Gale K. Parallel increases in striatal glutamic acid decarboxylase activity and mRNA levels in rats with lesions of the nigrostriatal pathway. Brain Res. 529:1990;345-348.
51. 2A antagonists with potent anti-cataleptic activity. Bioorg. med. Chem. Lett. 7:1997;2349-2352.
52. 2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology. 147:1999;90-95.
53. 1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance. J. med. Chem. 36:1993;2508-2518.
54. Tanaka Y., Nijima K., Mizuno Y., Yoshida M. Changes in gamma-aminobutyrate, glutamate, aspartate, glycine, and taurine contents in the striatum after unilateral nigrostiatal lesions in rats. Expl Neurol. 91:1986;259-268.
55. Timmerman W., Westerink B.H.C. Brain microdialysis of GABA and glutamate: what does it signify? Synapse. 27:1997;242-261.
56. Tossman U., Segovia J., Ungerstedt U. Extracellular levels of amino acids in striatum and globus pallidus of 6-hydroxydopamine-lesioned rats measured with microdialysis. Acta physiol. scand. 127:1986;547-551.
57. Vincent S.R., Nagy J.I., Fibiger H.C. Increased striatal glutamate decarboxylase after lesions of the nigrostriatal pathway. Brain Res. 143:1978;168-173.